Bombay High Court Imposes Heavy Costs in Trademark Infringement Suit Against Anrose Pharma for 'Zerodol' Copycat

In a stern verdict aimed at protecting brand equity in the pharmaceutical sector, the High Court of Judicature at Bombay has ruled in favor of IPCA Laboratories Limited in its long-standing trademark infringement suit against Anrose Pharma . Justice Arif S. Doctor, presiding over the matter, emphasized that the defendant’s adoption of the mark ZEROVOL–P for medicinal preparations was "dishonest" and carried a significant risk of confusion for the public.

A Calculated Breach of Trust

The dispute centers on the Plaintiff’s well-known trademark, ZERODOL , which IPCA Laboratories has used since 2003 for its extensive range of pain management pharmaceuticals. The Plaintiff argued that the defendant entered the market in 2013 with a deceptively similar product, ZEROVOL–P , intentionally seeking to capitalize on the reputation established by the "ZERODOL" name.

The case was listed as an "undefended suit" after Anrose Pharma failed to file a written statement or contest the proceedings, despite the serving of summons in 2014. The uncontroverted evidence indicated that the Plaintiff’s brand possessed immense goodwill, supported by substantial promotional expenditures and decades of consistent market presence.

The Standard of 'Imperfect Recollection'

Relying on established legal precedents such as K.R. Chinna Krishna Chettiar vs. Shri Ambal & Co. and Hiralal Prabhudas vs. Ganesh Trading Company , the Court applied the "average man of imperfect recollection" test.

Counsel for the Plaintiff effectively demonstrated that in the pharmaceutical domain, phonetic and visual similarities between marks can lead to life-impacting confusion. The Court concurred, noting that the likelihood of deception was imminent, especially as both products targeted pain relief, where a patient or a busy pharmacist might easily misidentify one for the other.

Key Observations from the Bench

Justice Arif S. Doctor’s judgment underscored the responsibilities of pharmaceutical manufacturers:

• On the Nature of Adoption: "The Defendant has not so much as even attempted to make out a case of honest or bona fide adoption of the mark ZEROVOL–P."
• On Potential for Deception: "Equally, given that the impugned mark is virtually identical to the Plaintiff's registered trade mark and both are used in respect of medicinal or pharmaceutical products, the likelihood of confusion is imminent."
• On Conduct and Costs: "This conduct is an additional factor that makes it clear that the defendant's adoption of the impugned mark was dishonest and was actuated in bad faith."
• On the Stricter Standard: "...the impugned products being medical products, a stricter order of costs must follow, as the Plaintiffs have profited at the potential risk to the public at large."

Judicial Retribution: A Stiff Penalty

Recognizing both the infringement of statutory rights and the defendant's lack of regard for the judicial process, Justice Doctor ordered a decree in terms of the prayer clauses, effectively restraining Anrose Pharma from any further use of the infringing mark.

Beyond the injunctive relief, the Court exercised its discretion under Section 35 of the Code of Civil Procedure, as amended by the Commercial Courts Act, 2015, to impose "exemplary costs." The defendant has been ordered to pay Rs. 15,00,000 to the Plaintiff within eight weeks, failing which an interest rate of 8% will apply. This ruling serves as a stark reminder that in the highly sensitive market of healthcare, courts will not tolerate brand piracy that compromises public safety and fair competition.